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Abstract 
Background / Aims 
Recent updates to the Nikkiso Aquarius continuous renal replacement 
therapy (CRRT) platform allowed us to develop a post dilution protocol for Regional 
Citrate Anticoagulation (RCA) using standard bicarbonate buffered, calcium 
containing replacement solution with Acid Citrate Dextrose Formula-A (ACD-A) as a 
citrate source. Our objective was to demonstrate the protocol was safe and 
effective. 
Methods 
Prospective audit of consecutive patients receiving RCA for CRRT within ICU, 
who were either contraindicated to heparin or had poor filter lifespan (<12 hours for 
2 consecutive filters) on heparin. 
Results 
We present the first 29 patients who used 98 filters. After excluding ‘non-
clot’ filter loss, 50% had duration of >27 hours. Calcium supplementation was 
required for 30 (30%) filter circuits, in 17/29 (58%) patients. One discontinuation due 
to metabolic alkalosis and no adverse bleeding events. 
Conclusion 
Post dilution RCA system is effective and simple to use on the Aquarius 
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Introduction 
Regional citrate anticoagulation (RCA) has been used routinely for continuous 
renal replacement therapy in treatment of critically ill patients for over 25 years [1] 
and is the recommended form of anticoagulation for both patients with and without 
contra-indication to heparin in the international Kidney Disease Improving Global 
Outcomes Acute Kidney Injury guidelines of 2012 [2].  Recent evidence has 
confirmed the superiority of regional citrate compared with systemic heparin 
anticoagulation both to maintain patency of the extracorporeal circuit and to reduce 
bleeding complications[3-6]. Despite this weight of favorable evidence uptake of RCA 
has been limited in many countries, including the UK[7]. Perception of RCA as 
complex to deliver and concerns regarding potential complications and additional 
cost of therapy may underlie this lack of enthusiasm. 
 In the UK CRRT is almost universally delivered in the intensive care unit (ICU) 
by the bedside nurse who, while highly skilled, has numerous demands and is not 
specialized to the administration of RRT. This system has the advantage that CRRT 
can be commenced rapidly at any time when clinically indicated. However, assurance 
of quality and safety for citrate in delivered by a single bedside nurse requires RCA 
delivery integrated into a microprocessor controlled CRRT device us ing simple 
reliable protocols. As a consequence, Heparin remains the anticoagulant of choice 
for CRRT in most UK ICUs while patients with contra-indications to systemic 
anticoagulation are managed with no anticoagulation. Wide use of no anti-
coagulation can result in poor circuit lifespan, inadequate delivered CRRT dose and 
blood loss associated with frequent filter clotting. 
RCA can be delivered in a number of CRRT modalities [8, 9]. In addition to 
citrate and calcium replacement solutions, calcium free dialysate or pre-dilution 
replacement fluid are required to maintain effective anticoagulation during dialysis, 
hemodiafiltration or pre-dilution hemofiltration, increasing expense and complexity. 
Conversely in post-dilution hemofiltration, conventional replacement solutions can 
spare the need for costly supplemental calcium infusions [10].   
Recent release of the Nikkiso Aquarius CRRT platform ‘Version 6-RCA’ 
(Nikkiso Europe GmbH, Hannover, Germany) has now enabled the integrated 
delivery of RCA-CRRT with machine-controlled pumps, enabling the development of 
RCA with this device in a UK ICU environment. This paper describes the 
implementation of a simple and reliable RCA protocol for post-dilution CRRT on the 
Aquarius device at the Royal London Hospital Adult Critical Care Unit (ACCU), 
London, UK.  The ACCU is a mixed medical / surgical ICU servicing a major London 
trauma center and renal unit where approximately 40% CRRT treatments have a 
contra-indication to heparin anticoagulation - presenting a significant impetus to the 
development of alternative anticoagulant strategies locally. 
 
Methodology 
RCA Protocol Development  
Development of the RCA protocol was constrained by availability of only a 
conventional haemofiltration replacement solution; Accusol (Nikkiso Europe GmbH, 
Hannover, Germany): a bicarbonate buffered solution, containing 1.75mmmol/L of 
Calcium (Table 1).  Use of this calcium containing replacement solution necessitated 
the use of post-dilution continuous veno-venous hemofiltration (CVVH), however 
this modality is simple to employ, and use of a single solution results in both 
logistical and cost advantages.  
Citrate was given in the form of Acid Citrate Dextrose Formula-A (ACD-A) 
solution (Haemonetics, Glasgow, UK) (Table 1); ACD-A solution is routinely used for 
anticoagulation of extra-corporeal circuits for apheresis and plasma exchange in the 
UK and for citrate anti-coagulated CRRT in Europe and the USA [11, 12].  As an 
advantage over the widely used tri-sodium citrate solution (TSC), ACD-A has both 
lower sodium content and less buffer generation after metabolism (2 molecules of 
bicarbonate per molecule of citrate in comparison with 3 from TSC). ACD-A solution 
(containing 113mmol/L citrate) was given to achieve a calculated pre-filter citrate 
concentration in blood of 2.8mmol/L [10] (i.e. 2.8/113 = 1/40 of blood flow). This 
citrate dose, while lower than in some RCA protocols, has been widely used for safe 
and effective RCA CRRT, achieving filter iCa2+ concentrations of around 0.35 mmol/L 
[10, 13], and was felt to represent the best balance between effective 
anticoagulation and risk of the development of metabolic alkalosis. 
 Development of the complete CVVH-RCA dosing schedule involved a 
stepwise process (Figure 1). The initial dose of 35 ml/kg/h was chosen to ensure a 
dosing schedule capable of accommodating the demands of initial treatment in 
sicker patients and to accommodate the local use of CRRT-dosing based on Ideal 
Body Weight (Devine formula). As ACD-A delivery also provides an element of pre-
dilution fluid (around 10%), the calculations were then iterated to maintain a 
consistent CRRT dose, before tabulation as post-dilution replacement rates, blood 
flow rates and ACD-A flow rates in weight ranges (<50, 50-59, 60-69, 70-79 and >80) 
(Table 2). Using this protocol thus involves only estimation of patient weight and 
programming of the indicated flow rates. Following the same process, a 25 ml/kg/h 
protocol was developed stepped down of dose if required (Table 2). 
We aimed to maintain plasma ionised Calcium in the range 0.9-1.2 [8]. 
Calcium replacement was principally by via the post-dilution Accusol replacement 
solution, which contains 1.75 mmol/L calcium, equating the initial calcium 
replacement employed in many other RCA protocols (3.5mmol/h with a 2L 
exchange). If required, additional calcium was administered via the integrated pump 
on the Aquarius device as a Calcium Chloride 10 mmol/L solution in 0.9% Saline. To 
avoid abrupt fall in iCa2+ additional Calcium was administered if initial arterial iCa2+ 
was <1.0 mmol/L or if iCa2+ fell below 0.9 mmol/L on 3hrly monitoring thereafter 
(Table 3).  
As a bicarbonate buffered replacement solution was used in addition to 
citrate there is the potential for development of metabolic alkalosis when using this 
CVVH-RCA protocol. To mitigate this tendency, a relatively low (2.8 mmol/L) dose of 
citrate and ACD-A solution (rather than tri-sodium citrate) was chosen. Arterial pH 
and bicarbonate were monitored every 3h. If whole blood HCO3 was >40 or pH >7.5 
while on a CRRT dose of 35 ml/kg/h, then intensity was reduced to 25 ml/kg/h (Table 
2), reducing bicarbonate donation by around 25%. If metabolic alkalosis persisted, a 
third 25 ml/kg/h RCA protocol a reduction in blood flow to 4 times hemofiltration 
rate (filtration ratio of 25%) in tandem with a reduction in citrate flow to keep the 
concentration in the blood at 1/40, was used to reduce citrate delivery by a further 
20% (Table 4). Persistent metabolic alkalosis despite these measures triggered a 
switch to non-RCA CRRT. 
Impaired citrate metabolism can occur in severe liver dysfunction or 
refractory shock with poor tissue perfusion causing citrate accumulation. Although 
RCA has been safely applied to patients with appropriate monitoring with chronic 
liver disease [14], in our developmental study we excluded patients with advanced 
chronic liver disease, acute liver or with refractory shock (Table 5).  In addition, we 
monitored the Total to Ionized Calcium ratio twice daily to assess for citrate 
accumulation and if this was greater than 2.5, RCA was discontinued. 
Both the 2.5% Dextrose content of ACD-A Solution and citrate itself represent 
sources of energy. ACD-A contains ~700 KJ/L energy of which 560 KJ/L would be 
delivered to the patient at a filtration ratio of 20%. This energy intake was factored 
into feeding requirements by clinician dieticians and blood glucose was monitored 
for hyperglycaemia 3 hourly. 
Pilot Service Implementation 
We considered the introduction of RCA as a clinically indicated service 
improvement and examined our implementation process in a prospective clinical 
audit. Patients were eligible if they had conventional reasons to need RRT within the 
ICU (new or on-going treatment) and were considered by the treating physician to 
either have a contraindication to heparin anticoagulation, or had a filter lifespan of 
<12h for >2 filter sets despite use of heparin. Contra-indications to commencement 
of RCA during the service implementation pilot, aimed at avoiding metabolic 
complications or citrate accumulation, are set out in Table 5. The first thirty 
consecutive CVVH-RCA treatments were evaluated. 
Systemic arterial blood gas analysis including ionized calcium, pH, 
bicarbonate, sodium and glucose were performed before RCA, one hour after 
initiation and then every three hours or as dictated by the Calcium replacement 
protocol. Central laboratory bloods for urea & electrolytes, calcium and magnesium 
levels were obtained before treatment and then 12 hourly allowing calculation of 
the total to ionized calcium ratio. We also recorded post-filter ionised calcium (these 
values were not used to adjust the protocol or treatment), circuit lifespan, quantity 




The first thirty patients treated with CVVH-RCA received 112 RCA 
anticoagulated CRRT circuits in total (Supplementary Table 2). One patient, whose 
diagnosis was necrotising pancreatitis due to a triglyceride level of 18.9 mmol/L was 
excluded from final analysis (14 filters median life span 6.5 hours range 4-12.5). The 
remaining 29 patients used 98 filters with a median (range) filter life span of 21 
hours (1-72). Reasons for filter cessation are shown in table 6. After excluding filter 
losses due to planned discontinuation for medical reasons (e.g. procedures, imaging, 
recovery of renal function) and technical failures of the CRRT circuit 50% of filters 
had duration of greater than 27 hours (Figure 2). 
 Metabolic characteristics of CVVH-RCA treatments are presented in Table 7.  
Post-filter [iCa2+] was measured twice a day to monitor the efficacy of the citrate 
protocol, across all samples taken the median value was 0.39, range 0.28-0.64 – only 
one measured value was >0.5 mmol/L. 
Calcium supplementation, in addition to the 1.75 mmol/L in Accusol, was 
required for 30 (30%) filter circuits, in 17/29 (58%) patients. Only three patients 
(eight filters) required supplementary calcium throughout the whole time they were 
receiving RCA-CVVH, one of who had necrotising pancreatitis. Five patients (nine 
filters) developed a need for additional calcium during treatment having not initially 
required it. In the remaining nine patients (thirteen filters) that required additional 
calcium on commencing RCA-CVVH the calcium infusion was administered for a 
median of 50% (range 1-91%) of the time on therapy.  
One patient discontinued RCA due to metabolic alkalosis refractory to 
protocol-directed adjustment of RCA therapy. There were no adverse bleeding 





This paper describes the successful development and implementation of an 
RCA protocol on the commonly utilizing integrated microprocessor-controlled pumps 
for citrate and calcium infusions on the Aquarius CRRT platform.  Several features of 
our protocol differ from other commercially available systems adding to the range of 
options available for clinicians. Post-dilution CVVH results in purely convective solute 
clearance with predictable dosing, and a conventional replacement solution has 
savings in terms of simplicity and minimizing cost of addition calcium solution.  Our 
protocol was well tolerated, despite use of the bicarbonate buffered replacement 
only one of 30 patients had to discontinue CVVH-RCA for alkalosis. Use of additional 
calcium was relatively low with 70% of circuits used not requiring additional calcium 
supplementation, representing potential savings in consumables and nursing time. 
There were no instances of clinical citrate accumulation. Filter lifespans were 
acceptable and similar to some previous reports of RCA-CRRT [15], but lower than 
median values (39-46 hours) reported in recent randomised trails comparing citrate 
to heparin [5, 6].  It should be noted that our patients were selected for having 
contraindications to heparin or prior poor filter lifespans and were thus likely to be 
predisposed to poorer filter lifespans, by comparison historical data suggests typical 
filter lifespan using no anticoagulation in our unit were three fold worse than those 
achieved with citrate in this pilot [16].  Based in our experience in this pilot, we 
expect that adoption of this protocol as standard therapy in unselected patients, 
together with the addition a higher citrate concentration option for early filter loss, 
will achieve substantial better filter lifespans - although our particular case mix may 
remain challenging even with optimal anticoagulation.  
Of note, in routine clinical practice filter lifespans are often poorer than those 
reported in patients recruited into controlled clinical trials even in very experienced 
hands [17].  In particular, other factors such as line position and length can affect 
filter lifespan independent of anticoagulation [18], in our pilot patients with catheter 
tips sited in the superior vena cava or right atrium had significantly longer lifespan 
than those in the brachiocephalic vein or in the inferior vena-cava (data not shown) 
emphasising that while effective use of RCA does not obviate the need for other 
elements of best practice in CRRT delivery such as obtaining best vascular access.   
Finally, this report focuses on the adoption of a novel therapy, not the 
performance of a fully developed protocol in a unit familiar with RCA therapy, in 
particular software modifications (in partnership with the manufacturer) were 
required to minimise low access pressure alarms associated with low blood flow 
rates through low resistance catheters that causes persistent interruption of therapy 
in some early patients, this was particularly relevant in the patients with end stage 
renal disease who were receiving intermittent haemodialysis through long, low-
resistance tunnelled catheters.  
 
On-going RCA development 
The success of this pilot has allowed adoption of citrate regional 
anticoagulation as the anticoagulant of choice for CRRT at the Royal London Hospital 
with familiarization with the RCA protocol embedded into rolling programs of nurse 
training. Building on the confidence using RCA during protocol development we have 
modified a set of exclusions and cautions (Supplementary table 3) for the use of 
RCA-CVVH as well as extending to a 6 hourly minimum frequency of blood gas 
monitoring in stable patients.  A final version of the current Royal London Hospital 
RCA-CVVH protocol is provided as a supplementary file incorporating these 
alterations.  
In addition, while generally successful, the variation in filter lifespans 
observed in our pilot suggests there might potential to optimise anticoagulation by 
increasing citrate dose in some patients. Accordingly, we have subsequently 
introduced a protocol increasing the citrate dose to a target circuit citrate 
concentration of 3.5mmol/L, using a 25 ml/kg/h exchange rate (Supplementary table 
1). This higher citrate dose, 25 ml/kg/h protocol provides a similar total citrate 
exposure to the basic 35 ml/kg/h protocol. As there can be considerable inter-
individual variations in citrate concentration required to achieve post filter iCa of 
0.25-0.35 prescription of citrate based on post filter iCa would be the ideal, however 
this requires accurate measurement low ionised calcium concentrations which may 
not be routinely available. We do not advocate routine monitoring of post-filter iCa 
to direct citrate dose with point of care analysers blood gas analysers as these 
measurements lie outside of the calibrated reference range and may be prone to 
inaccuracy [19]. We therefore recommend switching to the 3.5mmol/L citrate 
protocol in patients with clearly inadequate filter lifespan (<12h after optimisation of 
vascular access), as a pragmatic indicator of sub-optimal anticoagulation.   
 
Strengths and Limitations 
The principal strength of this service development project was our major 
focus on patient safety in a simple and reliable protocol. As a consequence, we did 
not observe any unexpected complications or major adverse events due to RCA. We 
provided 24-hour access to senior clinical staff (CK and JP) during the pilot period 
and developed a comprehensive audit tool that was able to rapidly detect 
biochemical changes. This cautious approach combined with close industry 
involvement during the development of this protocol allowed rapid technical 
support during early implementation and enabled successful clinical uptake. 
As this was not a clinical trial, our study is limited by a lack of direct 
comparison between RCA and other forms of anti-coagulation in equivalent patients. 
However, filter lifespan was superior to that historically achieved in comparable 
patients and our focus was to demonstrate successful pragmatic implementation of 
RCA with acceptable filter lifespan and not to prove superiority to other forms of 
anticoagulation such as heparin which are less suitable for our case-mix. The control 
of alkalosis might be better monitored using the calculation of the strong ion 
difference (SID) instead of pH and plasma bicarbonate. However, we chose a 
practical solution to allow our 240+ nursing staff and 30+ residents and fellows to 
use the system without addition calculation. Finally, we accept that by basing 
prescription on whole blood filtration ratio, instead of using the filtration fraction 
individualised to each patient’s haematocrit, we may have missed the influence of a 
key factor in filter lifespan. 
 
Conclusion 
A simple post dilution regional citrate anticoagulation system is effective and 
simple to use on the Nikkiso Aquarius platform. The use of ‘standard’ calcium 
containing replacement fluid reduces the need for supplementary calcium. A median 
filter life span of 27 hours (censored for reasons other than clotting) in complex 
patients with a relative contraindication to heparin was demonstrated and we 
expect this to improve further as familiarity improves and RCA is used as first choice 
anticoagulation in our unit.  
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Figure 1: A schematic representation of the steps required to define flow rates in the 
RCA protocol: Step 1: An initial CRRT dose of 35ml/kg/h. Step 2: Blood Pump Speed 
(ml/min) is set to five times the post-dilution rate (ml/h) to achieve Filtration Ratio of 
20%. Step 3: ACD-A solution rate (ml/h) was set to the hourly Blood Pump Speed ÷ 
40 to achieve a calculated pre filter citrate concentration of 2.8mmol/L. 
 
 
Figure 2: Kaplan Meier curve of filter survival censored for discontinuation due 
to technical (alarm or circuit errors) or medical reasons (discontinuation for 
procedures or imaging) – in this analysis median survival was 27 hours (dashed 
line) 
 
Table 1: Composition of fluids used in CVVH-RCA protocol 
 
Accusol 35 
(Mixed Solution, No Potassium) 
ACD-A 
(Acid Citrate Dextrose Solution A)  
Na+ 140  mmol/L Na+ 224 mmol/L 
Cl- 109.3  mmol/L H+ 115 mmol/L 
HCO3- 35  mmol/L Citrate3- 113 mmol/L 
Ca2+ 1.75  mmol/L Glucose 139 mmol/L 




Table 2: Pump settings to deliver a CRRT dose of 35 or 25 ml/kg/h 
 









35 25 35 25 35 25 
<50 1400 1100 120 100 180 150 
50-59 1800 1300 150 110 230 170 
60-69 2100 1500 180 130 270 200 
70-79 2400 1700 200 140 300 210 
>80 2700 1900 230 160 350 240 
 
 





DURING TREATMENT CALCIUM ADJUSTMENT 
ABG 
[iCa] 





CaCl infusion adjustment during RCA treatment 




Medical review  
& Correct iCa 
< 0.8 
•   Doctor to give 5ml, 10% CaCl (3.4 mmol) 
 ‘minijet’ by slow IV bolus via a central line 
 immediately 
• Increase CaCl infusion rate by 50 mL/h 
• If patient not on additional CaCl start at
 100 ml/kg 
If CaCl infusion already at 175 ml/h stop RCA 
& inform ICU Consultant immediately 
After 
1 hour 
0.8 –  
0.89 
75 mL/h  
(0.75 mmol/h) 
0.8 –  
0.89 
• Increase 1CaCl infusion by 25ml/h 
• If patient not on additional CaCl and start 
 at 75 ml/kg 
If CaCl infusion already at 175 ml/h stop RCA 





50 mL/h  
(0.5 mmol/h) 






0 mL/h  
(0 mmol/h) 
> 1.2 
• Decrease CaCl infusion by 25ml/h 
• If CaCl infusion off, then check systemic 
 [iCa] in 3 hours 





Table 4: Reducing the blood flow (whilst adjusting the citrate rate to maintain a 1/40 











<50 Reached minimum blood flow rate – DISCONTINUE RCA 
50-59 Reached minimum blood flow rate – DISCONTINUE RCA 
60-69 1500 100 150 
70-79 1700 120 180 
>80 1900 130 200 
 
 
Table 5: Contra-indications to commencement of RCA CRRT during pilot phase 
 
 Requirement for systemic anticoagulant (other than prophylaxis) 
 Chronic Liver Disease - Childs B or C 
 Acute Liver Injury with INR >2 or Lactate >4mmol/L 
 Post-hepatic resection 
 Severe shock with Noradrenaline >0.5mcg/kg/min and/or Lactate >4mmol/L 
 Arterial Blood ionized calcium <0.8µmol/L at commencement of RCA 
 Arterial Blood pH>7.5 or HCO3- >40mmol/L at commencement of RCA 
 Serum Sodium <120 or >160 at commencement of RCA 
 Uncontrolled hyperglycaemia requiring >6U/h Insulin to maintain blood 
sugars <10 
 
Table 6: Reason for CRRT cessation in patients receiving RCA 
 
 N (filters) Median (range) 
hours of therapy 
Coagulation related 
  Clot in filter 







Access issue 5 27 (5-44) 
Technical issue* 6 13 (3-22) 
Medical reason 11 27.5 (7-64) 
Set expired  5 72 (45-75) 
Reason not recorded 10 23 (6-66) 
*Persistent low access pressure alarms (3) and inadequate de-airing (3) 
 
Table 7: A summary of patients’ biochemistry and need for calcium supplementation 
during treatment with RCA 
 
 Median (Range) or Range 
Post filter iCa (mmol/L) 0.39 (0.28-0.64) 
Total:Ionised Ca Ratio 1.9 (1.01-2.59) 
pH 7.11-7.53 
Bicarbonate (mmol/L) 28.3-33.2 
Sodium (mmol/L) 130-155 
Patient time on additional calcium (min) 540 (27 – 2640) 
Patient total additional calcium delivered (mmol) 7.5 (0.25 - 62.5) 
 
Supplementary Material: Implementation of a simplified regional citrate anticoagulation 
protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium 
containing replacement solution.  Christopher J Kirwan, Ross Hutchison, Sherif Ghabina, 
Stephaine Schwarze, Abigail Beane, Susan Ramsay, Edward Thompson, John R Prowle  
 
Supplementary Table 1: An increased dose of Citrate with a delivered dose of 25 mL/kg/hr 
and filtration ratio of 20% 
IBW 
(kg) 






<50 1100 100 180 
50-59 1300 110 200 
60-69 1500 130 230 
70-79 1700 140 260 
>80 1900 160 300 
 
Supplementary Table 2: Demographics of the first 30 patients who received RCA for CRRT 
(Median, Range or Number, %) 
Age 65 (20-87) 
Male 17 (57%) 
Number of filters per patient 2 (1-13) 
Ideal body weight 66 (40-81) 
Ethnicity 
 - White 
 - Black 
 -  South Asian 






Primary cause of admission to critical care 
- Single organ AKI 
- Congestive cardiac failure 
- Lupus 
- Multi-organ failure 
- Ruptured Aortic Aneurysm 
- Sickle cell crisis 
- Post Cardiac Arrest 
- CVA 
- Pancreatitis 
- Pulmonary-renal vasculitis 
- Poly-trauma 
- Traumatic brain injury 
- Upper GI bleed 


















Supplementary Table 3: Updated cautions and contraindications for RCA post dilution CRRT 
following the successful pilot programme 
 
EXCLUSIONS CAUTIONS - Monitor closely 
 Acute Liver Failure with INR>3 
 Serum Sodium < 120 or > 160 
mmol/L  
 pH > 7.5 or HCO3 > 40 mmol/L 
 
 Chronic liver disease  
 Post hepatic Resection 
 Requiring >6 u/h insulin infusion 
 IBW> 90 kg (Use protocol 1 only) 
 Lactate >5 mmol/L 
 
 
 
